Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03485547

Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blastic Plasmacytoid Dendritic Cell Neoplasm Clinical Trial

Official title:
Phase 1 Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Clinical Trial Summary

This research study is studying a drug as a possible treatment for BPDCN. The intervention involved in this study is: Venetoclax

Clinical Trial Description

This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the safest dose of the investigational drug to use for further studies. "Investigational" means that the drug is being studied. The FDA (the U.S. Food and Drug Administration) has not approved venetoclax for this specific disease but it has been approved for other uses. Based on laboratory data where it was found that BPDCN cells die after treatment with Venetoclax, the investigators believe that this drug will be effective in treating patients with BPDCN. ;

Study Design

Related Conditions & MeSH terms

  • Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Neoplasms
Clinical Trial Details
NCT number NCT03485547
Study type Interventional
Source Dana-Farber Cancer Institute
Contact
Status Active, not recruiting
Phase Phase 1
Start date August 23, 2018
Completion date January 19, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03246906 - Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation Phase 2
Recruiting NCT04216524 - Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm Phase 2
Completed NCT00397579 - DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Phase 1/Phase 2
Terminated NCT03075553 - Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Phase 2
Completed NCT04317781 - Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant Phase 2
Recruiting NCT03113643 - SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Phase 1
Recruiting NCT06013423 - Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases Phase 2
Recruiting NCT05362773 - A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies Phase 1
Completed NCT02859623 - Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN) N/A
Completed NCT01231919 - MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Phase 1
Active, not recruiting NCT03386513 - Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN Phase 1/Phase 2
Completed NCT02652715 - Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma N/A
Active, not recruiting NCT03404193 - Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome Phase 2
Active, not recruiting NCT02220985 - Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Phase 2
Completed NCT00014235 - Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies N/A
Active, not recruiting NCT02159495 - Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Phase 1
Recruiting NCT03779854 - Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant Phase 2
Completed NCT02730312 - PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies Phase 1
Completed NCT03974971 - Blastic Plasmacytoid Dendritic Cell Neoplasm in Korean Population.